US Patent

US9238029 — Multiple PPI dosage form

Formulation · Assigned to Takeda Pharmaceuticals USA Inc · Expires 2026-01-17 · 0y expired

Vulnerability score 45/100 Strong — defensible against typical IPR challenges

What this patent protects

This patent protects a dosage form of a proton pump inhibitor (PPI) that releases two doses, each sufficient to raise plasma levels to at least 100 ng/ml.

USPTO Abstract

Herein provided are dosage forms (variously referred to as “formulations”) comprising a PPI that is released from the dosage form as a first and a second dose. Each dose of PPI is present in an amount sufficient to raise the plasma levels of the PPI to at least 100 ng/ml.

Drugs covered by this patent

Patent Metadata

Patent number
US9238029
Jurisdiction
US
Classification
Formulation
Expires
2026-01-17
Drug substance claim
No
Drug product claim
Yes
Assignee
Takeda Pharmaceuticals USA Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.